Actio Biosciences: Funding, Investors & Team (Sep 2026)
Actio Biosciences focuses on creating treatments for both rare and common diseases using genetics-oriented approaches. By utilizing human genetic insights and precision medicine techniques, the company identifies potential drug targets and is currently developing treatments for Charcot-Marie-Tooth disease type 2C and KCNT1-related epilepsy. Actio Biosciences conducts preclinical and Phase 1 studies to assess the safety, tolerability, and pharmacokinetics of their leading programs. In addition, the company collaborates with others, licenses technologies, and plans clinical trials to accelerate the development of treatments and potentially expand into more prevalent diseases.
Actio Biosciences has raised $66.0M across 1 funding round on record, the most recent a Series B of $66.0M announced in Jun 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Actio Biosciences Company Profile and Key Stats
Latest funding round on record: Jun 2025.
Actio Biosciences Funding Rounds
Actio Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Actio Biosciences Funding Compared to Other Biotechnology Startups
Actio Biosciences' latest round of $66.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Actio Biosciences in Biotechnology and San Diego
Companies Similar to Actio Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Actio Biosciences Funding FAQs
What does Actio Biosciences do?
Actio Biosciences focuses on creating treatments for both rare and common diseases using genetics-oriented approaches. By utilizing human genetic insights and precision medicine techniques, the company identifies potential drug targets and is currently developing treatments for Charcot-Marie-Tooth disease type 2C and KCNT1-related epilepsy. Actio Biosciences conducts preclinical and Phase 1 studies to assess the safety, tolerability, and pharmacokinetics of their leading programs. In addition, the company collaborates with others, licenses technologies, and plans clinical trials to accelerate the development of treatments and potentially expand into more prevalent diseases.
How much funding has Actio Biosciences raised?
Actio Biosciences has raised $66.0M across 1 round on record. The most recent is a Series B of $66.0M announced in Jun 2025.
When did Actio Biosciences last raise funding?
Actio Biosciences' most recent funding round on record is a Series B of $66.0M, announced in Jun 2025.
Who founded Actio Biosciences?
FundedIQ lists David Goldstein (Founder) at Actio Biosciences.
Where is Actio Biosciences headquartered?
Actio Biosciences is based in San Diego, California, United States.
How many employees does Actio Biosciences have?
Actio Biosciences is in the 11-50 employee band.
How does Actio Biosciences' funding compare to other Biotechnology startups?
Actio Biosciences' latest round of $66.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Actio Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Actio Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.